“I truly doubt that there is another psychedelic drug, anywhere, that can match this one for speed, for intensity, for brevity, and sensitive to dose, at least one that is active orally”
“To be on a trip & then to be back pretty much in two hours & really baseline in another hour? Most unusual. If there will ever be an acceptance of drugs such as these, in a psychotherapeutic context, a short duration is of extreme value to both the patient & the therapist.”
6/9
Greenway DNA: “Methods & Systems for Providing a Personalized Treatment Regimen Using Cannabinoid or Psychedelic Compounds”
Providing “personalized psychedelic compound treatment regimen” to patient based on genotypes of single nucleotide polymorphisms from genetic testing
7/9
Small Pharma: “Deuterated N,N-Dimethyltryptmine Compounds”
“compositions and methods which enable a finely tuned single dose to maintain a patient in full dissociation from the external world, referred to herein as ‘DMT space,’ for a therapeutically optimised duration”
“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”
1/12
The patents claimed medical preparations of:
(1) ibogaine, iboga alkaloid extract, or total extract; plus
(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline
“The best results have been obtained with” MDA
The combination “forms an excellent medicine"
2/12
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”
A primary difference between the new ‘257 & the first ‘175 patent is:
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx